While ABT stock appears poised to reach the year’s halfway mark in ignominy, the options market is quietly signaling a possible recovery.

Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Abbott Laboratories (NYSE:ABT) is scheduled to announce its second-quarter earnings on Thursday, July 17, 2025. For traders who focus on events, examining the historical reactions of the stock to ...

ABT stock fell to a 52-week low of $90.29 in intraday trading as weak Covid-19 testing and U.S. pediatric nutrition, and other sectoral concerns weighed on its performance. ・FIG stock fell to a ...

Abbott Laboratories (NYSE:ABT) has greatly exceeded the broader S&P 500 index this year, with its stock price increasing by 18% compared to the S&P 500’s 6% rise. This strong performance is due to the ...

Alpha Wealth Funds, LLC, an investment management company, released its Q1 2025 letter for the “Insiders Fund”. A copy of the ...

Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the August 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is ...

Carillon Tower Advisers, an investment management company, released its first-quarter 2026 investor letter for the “Carillon ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Is ABT a good stock to buy? We came across a bullish thesis on Abbott Laboratories on Compounding Dividends’s Substack by TJ Terwilliger. In this article, we will summarize the bulls’ thesis on ABT.